ENTX (Entera Bio) Tariff Resilience Score: 5/10 (As of Jul. 02, 2026)


ENTX Entera Bio Ltd ENTX
23 GF Score
Price $1.66
! 2 Warning Signs
View Full Analysis

What is Entera Bio Tariff Resilience Score?

Entera Bio ENTX -2.92% 23 Tariff Resilience Score is 5 as of Jul. 02, 2026. GuruFocus rates ENTX with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 1,374 Biotechnology companies, Entera Bio ranks better than 62.23% on this metric.

Entera Bio has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Entera Bio has Entera Bio's international supply chain for pharmaceutical ingredients exposes it to tariff risks. While it can source from multiple suppliers, its pricing power is limited, making it moderately vulnerable to tariff changes.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Entera Bio might have Average Resilient.

Entera Bio  (NAS:ENTX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Entera Bio Tariff Resilience Score Related Terms

ENTX vs HRTX, OKYO, EDSA: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Entera Bio's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entera Bio Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entera Bio's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Entera Bio's Tariff Resilience Score falls into.


ENTX
23GF Score
Entera Bio Ltd ENTX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Entera Bio (ENTX) has a Tariff Resilience Score of 5 as of Jul. 02, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Entera Bio ranks #519 out of 1374 companies in the Biotechnology industry, placing it in the top 37.8%.
Is Entera Bio's Tariff Resilience Score too high?
Entera Bio's current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Entera Bio's value of 5 is 25% above this industry median. Based on the distribution chart, Entera Bio ranks #519 out of 1374 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Entera Bio has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Entera Bio's Tariff Resilience Score compare to HRTX and OKYO?
According to the Biotechnology industry distribution chart, Entera Bio ranks #519 out of 1374 companies for Tariff Resilience Score. This puts Entera Bio in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Entera Bio's value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Entera Bio's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entera Bio's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entera Bio stock overvalued right now?
Entera Bio (ENTX) has a current Tariff Resilience Score of 5. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Entera Bio's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Entera Bio (ENTX), the current Tariff Resilience Score is 5 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entera Bio Business Description

Other Exchanges 5DT:Germany
Address Kiryat Hadassah, Minrav Building - Fifth Floor, Hadassah Bio Park, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
23GF Score

Get the complete analysis for ENTX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.66
Price